

Figure S1.

ChiP analysis of WM164 wild type melanoma cell line stimulated with IL-6 (30ng/mL) and collected at baseline (time 0) or at 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours after stimulation, assessed with PS5-CTD Pol II **(A)** and acetyl H3 **(B)** antibodies, followed by quantitative real-time PCR analysis of the 7 different primers described above (detailed in Table 1). **(C)** WM164 cells were treated with IFN γ , and then subjected to immunoblot to evaluate HDAC6, PD-L1, ac-Tubulin and GAPDH. **(D)** WM164 cells were treated with IFN γ , then total RNA was isolated and the expression of PD-L1 analyzed by qRT-PCR. NT, HDAC6KD and STAT3KD WM164 melanoma cells were transfected with either STAT3C-flag plasmid **(E)** or empty vector **(F)** and then stimulated with IFN γ (100 ng/mL) or left untreated. Then, PD-L1 was evaluated by flow cytometry.

Figure S2.

WM164 cells were treated with LBH589 10nM or 20nM **(A and C)** or MGCD0103 1 μ M or 2 μ M **(B and D)** for 24 hours and then stimulated with IL-6 or left untreated. Then, the presence of HDAC6, STAT3, P-STAT3 Y705, P-STAT3 S727, acetylated STAT3, PD-L1 and GAPDH was assessed by flow cytometry **(C and D)** and immunoblot **(E and F)**.

Figure S3.

(A) NT and HDAC6KD B16-F10 murine melanoma cells were stimulated with IL-6 (30ng/ml) or left untreated. Next, the presence of HDAC6, acetylated tubulin, STAT3, P-STAT3Y705, P-STAT3-S727, acetylated STAT3 and GAPDH was assessed by immunoblot. **(B)** B16-F10-luc melanoma cell line were treated with the HDAC6 inhibitor Nexturastat for 24 hour and then stimulated with IL-6 (30 ng/mL) or left untreated. The presence of HDAC6, acetylated tubulin,


STAT3, P-STAT3Y705, P-STAT3-S727, acetylated STAT3 and GAPDH was assessed by immunoblot.

Figure S4.


NT and HDAC6KD WM164 human melanoma cells were stimulated with IL-6 (30ng/ml) or left untreated. Next, the presence of PD-L2, TRAIL-R1, TRAIL-R2, B7-H3 and B7-H4 were measured by western blot (A) and flow cytometry (B).

Figure Supplementary 1


A




B




C



D



E



F




Figure Supplementary 2






Figure Supplementary 3

